Recombinant foamy virus vectors for medicinal, and diagnostic uses, and processes for preparing recombinant foamy virus vectors
AssigneeBayer Aktiengesellschaft
InventorsVolker ter Meulen, Axel Rethwilm
Life of this patent
Estimating the term…
Abstract
The present invention relates to the preparation of novel vector systems which are generated by in-vitro recombination, using gene technology, of nucleic acids from foamy virus species and of exogenous nucleic acid, and are produced by suitable host cells or by recombinantly altered packaging cell lines. The recombinant preparation of particularly suitable packaging cell lines is likewise a constituent of this invention. The invention is distinguished by the safe and efficient transfer by foamy virus vectors of therapeutic and other genes into eukaryotic cells.
Claims19
Infectious or non-infectious DNA of human spumaretrovirus pHSRV-1 or pHSRV-2 comprising an internal deletion, that spans a portion of each of the bel-1, bel-2 and bel-3 genes or an internal deletion that spans a portion of each of the bel-2 and bel-3 genes, but not the bel-1 gene.
Infectious or non-infectious DNA selected from the group consisting of pFOV-1, pFOV-2, pFOV-3, pFOV-4, pFOV-5 and pFOV-6.
Infectious or non-infectious DNA of human spumaretrovirus pHSRV-1 or pHSRV-2 comprising a deletion into which there has been inserted an exogenous nucleic acid, said deletion spanning a portion of each of the bel-1, bel-2 and bel-3 genes or spanning a portion of each of the bel-2 and bel-3 genes, but not the bel-1 gene.
Infectious or non-infectious DNA of human spumaretrovirus pHSRV-1 or pHSRV-2 comprising a deletion into which there has been inserted an exogenous nucleic acid, said deletion being in the bel-1, bel-2 or bel-3 genes.
Dependencies are inferred from the claim text.